Compare AbbVie Inc (ABBV) vs Hershey Co (HSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Hershey Co — how do they compare? AbbVie Inc trades at $254.12 (market cap $449.91B), while Hershey Co trades at $176.01 (market cap $35.69B). The key difference: AbbVie Inc is far larger — about 12.6× Hershey Co's market cap, and Hershey Co pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| ABBV | HSY | |
|---|---|---|
Market Cap | $449.91B | $35.69B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $236.28 |
52-Week Low | $184.85 | $161.95 |
Enterprise Value | $513.38B | $40.49B |
Dividend Yield | 2.72% | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Hershey (HSY) trades at $175.95, down 3.4% over the past day, with a bearish technical signal but strong recent earnings beats. The stock shows a high P/E ratio of 33.06 and a net income margin of 9.12%, supported by consistent cash flow from operations of $2.28B in 2025. Recent corporate actions include a $1.45 dividend and executive appointments, while cocoa cost pressures show signs of easing according to MarketBeat (July 1, 2026).
The outlook is mixed: analyst consensus targets $211.27 with 65.72% hold ratings, indicating cautious optimism amid valuation concerns. Key risks include commodity inflation and competitive pressures, but margin recovery and dividend yield near 3.2% offer potential for income-focused investors. Upside depends on sustained earnings growth and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
